Taysha Gene Therapies, Inc. Common Stock (TSHA) is a publicly traded Healthcare sector company. As of May 21, 2026, TSHA trades at $5.20 with a market cap of $1.56B and a P/E ratio of -14.25. TSHA moved +5.69% today. Year to date, TSHA is +12.27%; over the trailing twelve months it is +87.37%. Its 52-week range spans $1.05 to $7.30. Analyst consensus is strong buy with an average price target of $12.10. Rallies surfaces TSHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TSHA SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $5.20 |
| Market Cap | $1.56B |
| P/E Ratio | -14.25 |
| EPS | $-0.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.30 |
| 52-Week Low | $1.05 |
| Volume | 14 |
| Avg Volume | 0 |
| Revenue (TTM) | $7.47M |
| Net Income | $-129.88M |
| Gross Margin | 0.00% |
10 analysts cover TSHA: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.10.